Toxic risk of stereotactic body radiotherapy and concurrent helical tomotherapy followed by erlotinib for non-small-cell lung cancer treatment - case report

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Hsieh, Chen Hsi ^a,c   Chang, Hou Tai ^a   Lin, Shih Chiang ^a   Chen, Yu Jen ^c,d   Wang, Li Ying ^e   Hsieh, Yen Ping ^f   Chen, Chien An ^a   Chong, Ngot Swan ^a   Lin, Shoei L ^g   Chen, Chun Yi ^g   Shueng, Pei Wei ^a,b  

^a FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^b NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d MACKAY MEMORIAL HOSPITAL   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^f ASIA UNIVERSITY   (Taiwan)

^g TAIPEI HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; ERLOTINIB; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

AGED; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DYSPNEA; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG NON SMALL CELL CANCER; LUNG VOLUME; MAINTENANCE THERAPY; MALE; MULTIMODALITY CANCER THERAPY; RADIATION PNEUMONIA; STEREOTACTIC BODY RADIATION THERAPY; THERAPY EFFECT; TOMOTHERAPY; TUMOR VOLUME; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; CANCER STAGING; COMPUTER ASSISTED RADIOTHERAPY; DRUG ANTAGONISM; ENZYMOLOGY; FATALITY; LUNG TUMOR; RADIATION DOSE FRACTIONATION; RADIOGRAPHY; RADIOSURGERY; TIME; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; DOSE FRACTIONATION; DYSPNEA; FATAL OUTCOME; HUMANS; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RADIATION PNEUMONITIS; RADIOSURGERY; RADIOTHERAPY, ADJUVANT; RADIOTHERAPY, CONFORMAL; RECEPTOR, EPIDERMAL GROWTH FACTOR; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 78650659959     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-696     Document Type: Article

References (21)

1. Jackman DM, Yeap BY, Lindeman NI, Fidias P, Rabin MS, Temel J, Skarin AT, Meyerson M, Holmes AJ, Borras AM, et al. Phase II clinical trial of chemotherapy-naive patients ≥ or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 2007, 25(7):760-766. 10.1200/JCO.2006.07.5754, 17228019.
2. Hodge W, Tome WA, Jaradat HA, Orton NP, Khuntia D, Traynor A, Weigel T, Mehta MP. Feasibility report of image guided stereotactic body radiotherapy (IG-SBRT) with tomotherapy for early stage medically inoperable lung cancer using extreme hypofractionation. Acta Oncol 2006, 45(7):890-896. 10.1080/02841860600907329, 16982555.
3. Slotman BJ, Njo KH, de Jonge A, Meijer OW, Karim AB. Hypofractionated radiation therapy in unresectable stage III non-small cell lung cancer. Cancer 1993, 72(6):1885-1893. 10.1002/1097-0142(19930915)72:6<1885::AID-CNCR2820720616≥3.0.CO;2-7, 8395967.
4. Choong NW, Mauer AM, Haraf DJ, Lester E, Hoffman PC, Kozloff M, Lin S, Dancey JE, Szeto L, Grushko T, et al. Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. J Thorac Oncol 2008, 3(9):1003-1011. 10.1097/JTO.0b013e31818396a4, 18758303.
5. Yorke ED, Jackson A, Rosenzweig KE, Merrick SA, Gabrys D, Venkatraman ES, Burman CM, Leibel SA, Ling CC. Dose-volume factors contributing to the incidence of radiation pneumonitis in non-small-cell lung cancer patients treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 2002, 54(2):329-339. 10.1016/S0360-3016(02)02929-2, 12243805.
6. Choi YW, Munden RF, Erasmus JJ, Park KJ, Chung WK, Jeon SC, Park CK. Effects of radiation therapy on the lung: radiologic appearances and differential diagnosis. Radiographics 2004, 24(4):985-997. discussion 998, 10.1148/rg.244035160, 15256622.
7. Liu V, White DA, Zakowski MF, Travis W, Kris MG, Ginsberg MS, Miller VA, Azzoli CG. Pulmonary toxicity associated with erlotinib. Chest 2007, 132(3):1042-1044. 10.1378/chest.07-0050, 17873198.
8. Belderbos JS, Heemsbergen WD, De Jaeger K, Baas P, Lebesque JV. Final results of a Phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2006, 66(1):126-134. 10.1016/j.ijrobp.2006.04.034, 16904518.
9. Fowler JF. The first James Kirk memorial lecture. What next in fractionated radiotherapy?. Br J Cancer Suppl 1984, 6:285-300. 2149181, 6365141.
10. Graham MV, Purdy JA, Emami B, Harms W, Bosch W, Lockett MA, Perez CA. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 1999, 45(2):323-329. 10.1016/S0360-3016(99)00183-2, 10487552.
11. Baisden JM, Romney DA, Reish AG, Cai J, Sheng K, Jones DR, Benedict SH, Read PW, Larner JM. Dose as a function of lung volume and planned treatment volume in helical tomotherapy intensity-modulated radiation therapy-based stereotactic body radiation therapy for small lung tumors. Int J Radiat Oncol Biol Phys 2007, 68(4):1229-1237. 10.1016/j.ijrobp.2007.03.024, 17513066.
12. Carrion RP, Gracian AC, Hernandez PS. Erlotinib as a single agent in select subsets of patients with advanced non-small-cell lung cancer. Clin Lung Cancer 2007, 8(7):425-428. 10.3816/CLC.2007.n.026, 17681095.
13. Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, Kris MG, Tran HT, Klein P, Li X, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005, 23(25):5892-5899. 10.1200/JCO.2005.02.840, 16043829.
14. Kitani H, Kosaka T, Fujihara T, Lindquist K, Elkind MM. The "recall effect" in radiotherapy: is subeffective, reparable damage involved?. Int J Radiat Oncol Biol Phys 1990, 18(3):689-695. 10.1016/0360-3016(90)90078-X, 2318703.
15. Chinnaiyan P, Huang S, Vallabhaneni G, Armstrong E, Varambally S, Tomlins SA, Chinnaiyan AM, Harari PM. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res 2005, 65(8):3328-3335.
16. Milano MT, Constine LS, Okunieff P. Normal tissue toxicity after small field hypofractionated stereotactic body radiation. Radiat Oncol 2008, 3:36. 10.1186/1748-717X-3-36, 2596155, 18976463.
17. Yamashita H, Nakagawa K, Nakamura N, Koyanagi H, Tago M, Igaki H, Shiraishi K, Sasano N, Ohtomo K. Exceptionally high incidence of symptomatic grade 2-5 radiation pneumonitis after stereotactic radiation therapy for lung tumors. Radiat Oncol 2007, 2:21. 10.1186/1748-717X-2-21, 1894806, 17553175.
18. Shueng PW, Lin SC, Chang HT, Chong NS, Chen YJ, Wang LY, Hsieh YP, Hsieh CH. Toxicity risk of non-target organs at risk receiving low-dose radiation: case report. Radiat Oncol 2009, 4:71. 10.1186/1748-717X-4-71, 2806297, 20043839.
19. Hsieh CH, Hsieh YJ, Liu CY, Tai HC, Huang YC, Shueng PW, Wu LJ, Wang LY, Tsai TH, Chen YJ. Abdominal irradiation modulates 5-Fluorouracil pharmacokinetics. J Transl Med 2010, 8:29. 10.1186/1479-5876-8-29, 2861020, 20338060.
20. Nanda A, Dias-Santagata DC, Stubbs H, O'Hara CJ, Zaner KS, Lynch TJ, Willers H. Unusual tumor response and toxicity from radiation and concurrent erlotinib for non-small-cell lung cancer. Clin Lung Cancer 2008, 9(5):285-287. 10.3816/CLC.2008.n.044, 18824451.
21. Dauendorffer JN, Dupuy A. Radiation recall dermatitis induced by erlotinib. J Am Acad Dermatol 2009, 61(6):1086. 10.1016/j.jaad.2009.04.033, 19925938.